

PROGRAM

**Legislative Issues of Interest to Universities,
Non-Profits and the Pharmaceutical Industry**

February 27, 2003

TABLE OF CONTENTS

PROGRAM

**Legislative Issues of Interest to Universities,
Non-Profits and the Pharmaceutical Industry**

February 27, 2003

- A Agenda**
- B List of Attendees**
- C Notes from last meeting (September 26, 2002)**
- D PowerPoint slides: "Protection of Collaborative Research – A PhRMA Perspective"**
- E Hatch-Waxman regulatory reform: materials**
- F Collaborative research reform: materials**
- G International patent issues: materials**
- H Experimental use/research exception issues: materials**
- I Animal testing issues: materials**
- J Miscellaneous**

A

PROGRAM

Legislative Issues of Interest to Universities, Non-Profits and the Pharmaceutical Industry

February 27, 2003

- 11:30 a.m. Meeting Begins
- 11:40 a.m. Participants are seated
- 11:45 a.m. Opening Remarks: Sheldon Steinbach
- 11:55 a.m. Self-introduction of participants and their organizations
- 12:00 noon Bruce Kuhlik, General Counsel, PhRMA
"Current State of Play: Hatch-Waxman Act"
- 12:20 p.m. Lunch Served
- 12:30 p.m. Andy Cohn, Director of Public Policy, WARF
Pat Harsche, President, AUTM
"Technology Transfer—University Priorities"
- 12:45 p.m. Sean Darragh, Vice President, PhRMA
"Patents and the International Situation"
- 1:00 p.m. Richard Turman, AAU
"Animal Terrorism and Legal Rights for Animals"
from the university perspective
- 1:15 p.m. Valerie Volpe, PhRMA
"The Bayh-Dole Act: Is it Under Political Attack and What Should be
Done"
from a PhRMA perspective
- 1:30 p.m. "The Research and Experimental Exception in the Patent Law"
from a university/medical school perspective
- 1:45 p.m. Closing Remarks: Sheldon Steinbach
"Where Do We Go From Here?":
Regional conferences, Hill briefings, media,
Cross-fertilization
- 2:00 p.m. Adjournment

B

LIST OF ATTENDEES
FEBRUARY 27, 2003 MEETING

Sheldon Steinbach, Esq.
Vice President and General Counsel
American Council on Education
1 DuPont Circle, N.W.
Suite 836
Washington, DC 20036
202-939-9361
sheldon_steinbach@ace.nche.edu

Bruce Kuhlik
Senior Vice President & General Counsel
Pharmaceutical Research and
Manufacturers Association
1100 Fifteenth Street, N.W.
Washington, DC 20005
202-835-3469
bruce.kuhlick@phrma.org

Valerie Volpe
Senior Director - Alliance Development
Pharmaceutical Research and
Manufacturers Association
1100 Fifteenth Street, N.W.
Washington, DC 20005
202-835-3588
vvolpe@phrma.org

Sean Darragh
Deputy Vice President, International Policy
Pharmaceutical Research and
Manufacturers Association
1100 Fifteenth Street, N.W.
Washington, DC 20005
202-835-3458
sean.darragh@phrma.org

Erika King
Assistant General Counsel
Pharmaceutical Research and
Manufacturers Association
1100 Fifteenth Street, N.W.
Washington, DC 20005
202-834-3400
erika.king@phrma.org

Richard Harpel
Director, Federal Relations –
Higher Education National Association
of State Universities and Land-Grant
Colleges
1307 New York Avenue, N.W.
Suite 400
Washington, D.C. 20005-4722
202-478-6040
rharpel@nasulgc.org

Robert Hardy
Associate Director
Council on Governmental Relations
1200 New York Avenue, N.W.
Suite 320
Washington, D.C. 20005
202-289-6655
rhardy@cogr.edu

Richard J. Turman
Director of Federal Relations
Association of American Universities
1200 New York Avenue, N.W.
Suite 550
Washington, D.C. 20005
202-408-7500
richard_turman@aau.edu

Stephen Heinig
Senior Staff Associate, Division for
Biomedical and Health Sciences Research
Association of American Medical Colleges
2450 N Street, N.W.
Washington, D.C. 20037
202-828-0488
sheinig@aamc.org

Andy Cohn
Director of Public and Governmental
Relations
Wisconsin Alumni Research Foundation
614 Walnut Street
Madison, WI 53705
608-263-2821
cohn@warf.ws

Norman J. Latker, Esq.
Browdy & Niemark
624 9th Street, N. W.
Washington, DC
20001 202-628-5197
njl@browdyneimark.com

Patricia Harsche
Vice President, Planning
& Business Development
Fox Chase Cancer Center
7701 Burholme Avenue
Philadelphia, PA 19111
215-728-2468
p_harsche@fccc.edu

Michael J. Remington, Esq.
Drinker Biddle & Reath LLP
1500 K Street, N.W.
Suite 1100
Washington, D.C. 20005
202-842-8839
michael.remington@dbr.com

Chris Wilson
Government Affairs Specialist
Drinker Biddle & Reath LLP
1500 K Street, N.W.
Suite 1100
Washington, D.C. 20005
202-354-1324
wilsonce@dbr.com

C

MEMORANDUM

TO: Meeting Participants

FROM: Chris Wilson
Michael J. Remington

DATE: September 30, 2002

RE: Luncheon Meeting Concerning the Bayh-Dole Act

Public policy and governmental relations representatives of various university and medical research associations and one university foundation as well as representatives of the Pharmaceutical Research and Manufacturers Association (PhRMA) met on September 26, 2002 at 11:30 a.m. at the Jefferson Hotel in Washington, D.C. The purpose of the meeting was twofold: (1) for the attendees to get to know each other better; and (2) to discuss the current legislative proposals affecting the pharmaceutical industry and the university community and their negative impact on the Bayh-Dole Act, and in doing so to share the policy goals and prerogatives of the participants' organizations in an attempt to find common ground.

Present at the luncheon meeting were the following:

- Sheldon Steinbach, Esq., Vice President and General Counsel, American Council on Education (ACE)
- Richard Harpel, Director, Federal Relations-Higher Education, National Association of State Universities and Land-Grant Colleges (NASULGC)
- Kate Phillips, President, Council on Governmental Relations (COGR)
- Robert Hardy, Associate Director, Council on Governmental Relations (COGR)
- Richard J. Turman, Director of Federal Relations, Association of American Universities (AAU)
- Michael J. Remington, Esq., Drinker Biddle & Reath LLP
- Christopher E. Wilson, Government Affairs Specialist, Drinker Biddle & Reath LLP
- Stephen Heinig, Senior Staff Associate, Division for Biomedical and Health Sciences Research, Association of American Medical Colleges (AAMC)
- Andy Cohn, Director of Public and Governmental Relations, Wisconsin Alumni Research Foundation (WARF)
- Norman J. Latker, Esq., Browdy & Niemark
- John T. Kelly, M.D., Ph.D., Senior Vice President, Scientific & Regulatory Affairs, PhRMA
- Valerie Volpe, Senior Director-Alliance Development, PhRMA
- Rachel Keresztes, Director of Policy, PhRMA
- Missy Jenkins, Senior Director, Federal Affairs, PhRMA

- Sara Radcliffe, Director, Science and Regulatory Affairs, PhRMA
- Gregory J. Glover, M.D., Esq., Ropes & Gray

OPENING REMARKS

Valerie Volpe welcomed all participants and provided a brief overview of her job duties and the priorities of PhRMA in forging working relationships with parties that share common interests. She additionally stated that PhRMA perceives the legislation proposed by Sens. McCain and Schumer (S. 812) and recently passed by the Senate, and House companion legislation (H.R. 5311), as a "threat" and that she hoped it could be discussed over the course of the meeting.

Dr. John Kelly echoed Valerie's remarks and additionally noted that collaboration between universities and the pharmaceutical industry is "critical" as "future progress is not ensured." Both Valerie and John made the fundamental point that pharmaceutical companies and universities engage in their respective activities to benefit the public (*e.g.*, the patient).

Lastly, Mike Remington welcomed all and made special note of Norm Latker's presence at the meeting by commenting on Norm's vast institutional memory regarding the creation of the Bayh-Dole Act. Mike also noted that a meeting agenda had been prepared to ensure a balanced and open exchange of the various perspectives.

OPENING PRESENTATION

As a foundation for discussion among the participants, Dr. Gregory Glover gave a Power Point presentation entitled: "Importance of Patents to the Discovery & Development of New Treatments & Cures." Greg's presentation consisted of a general overview of the pertinence of patent law to the research and development of pharmaceutical products by universities and the pharmaceutical industry. Additionally, he provided a specific discussion regarding the impact that the Bayh-Dole Act and the Hatch-Waxman Act have had on the development of health care products. Lastly, Greg outlined PhRMA's key concerns with regards to S. 812 and H.R. 5311, stating that the proposed legislation seeks to alter the spirit of the Bayh-Dole Act.

As a follow-up to Greg's discussion of S. 812 and H.R. 5311, Richard Harpel asked him whether or not the proposed legislation had any redeeming value or if the legislation should be "killed" outright. Greg, Missy Jenkins, Valerie Volpe and Rachel Kerestes all agreed the proposed legislation should be "killed" and that the two bills were solutions in search of a problem.

Upon completion of Greg's presentation, John suggested that it would be beneficial if Greg's Power Point presentation was converted to document form and distributed to all participants. All attendees agreed.